BLIS Technologies (NZSE:BLT) Other Current Receivables: NZ$0.02 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BLIS Technologies Other Current Receivables?

BLIS Technologies NZSE:BLT Other Current Receivables is NZ$0.02 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

BLIS Technologies's Other Current Receivables for the quarter that ended in Mar. 2026 was NZ$0.02 Mil.

BLIS Technologies's quarterly Other Current Receivables declined from Mar. 2025 (NZ$0.01 Mil) to Sep. 2025 (NZ$0.00 Mil) but then increased from Sep. 2025 (NZ$0.00 Mil) to Mar. 2026 (NZ$0.02 Mil).

BLIS Technologies's annual Other Current Receivables increased from Mar. 2024 (NZ$0.00 Mil) to Mar. 2025 (NZ$0.01 Mil) and increased from Mar. 2025 (NZ$0.01 Mil) to Mar. 2026 (NZ$0.02 Mil).

BLIS Technologies Other Current Receivables Related Terms

BLIS Technologies Other Current Receivables Historical Data

* Premium members only.

The historical data trend for BLIS Technologies's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLIS Technologies Other Current Receivables Chart

BLIS Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 -0.00 0.00 0.01 0.02

BLIS Technologies Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.02

BLIS Technologies Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NZ$0.02 Mil mean?
BLIS Technologies (NZSE:BLT) has a Other Current Receivables of NZ$0.02 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BLIS Technologies and its competitors.
Is BLIS Technologies' Other Current Receivables too high?
BLIS Technologies' current Other Current Receivables is NZ$0.02 Mil.
How does BLIS Technologies' Other Current Receivables compare to VRTX and REGN?
BLIS Technologies' Other Current Receivables of NZ$0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BLIS Technologies and its competitors. BLIS Technologies's current Other Current Receivables is NZ$0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 15% below its estimated fair value. The current Other Current Receivables is NZ$0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Other Current Receivables is NZ$0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BLIS Technologies Business Description

Address 399 Moray Place, Dunedin Central, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.